Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 34.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 243,760 shares of the company’s stock after purchasing an additional 62,178 shares during the period. Franklin Resources Inc. owned approximately 0.85% of Krystal Biotech worth $43,774,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in KRYS. Key Financial Inc acquired a new position in Krystal Biotech during the second quarter worth $28,000. Blue Trust Inc. increased its position in shares of Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter worth $40,000. Values First Advisors Inc. purchased a new stake in shares of Krystal Biotech during the third quarter worth $53,000. Finally, Quest Partners LLC purchased a new stake in shares of Krystal Biotech during the second quarter worth $71,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $169.04 on Wednesday. The firm has a market capitalization of $4.86 billion, a PE ratio of 95.50 and a beta of 0.80. The business’s fifty day moving average price is $181.01 and its 200 day moving average price is $185.37. Krystal Biotech, Inc. has a 12 month low of $107.50 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the firm posted ($0.67) earnings per share. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Chardan Capital reissued a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a report on Thursday, December 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has a consensus rating of “Buy” and an average target price of $206.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).